CERo Therapeutics Holdings, Inc. announced that it will present preclinical data for its lead compound, CER-1236, targeting ovarian cancer during the Spring Scientific meeting of the Society for ...
I believe in the importance of merit. Explore HBR HBR Store About HBR Manage My Account Follow HBR Harvard Business Publishing: Copyright ©2025 Harvard Business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback